A commonsense approach for public health

31 Dec 2017 · 2 min read
We are delivering better, more satisfying alternatives for adult smokers, so that the largest number of those who don't quit can switch to them.
People sitting outside by a lake

The World Health Organization estimates that there will still be over a billion smokers by 2025.1 With so many people choosing to smoke, it makes sense that they should have access to and accurate information about better alternatives to cigarettes. Why would anyone deny them this opportunity?

A few important steps are needed to make this commonsense approach a reality for millions of smokers. First, you need to invent better alternatives to cigarettes. Second, these alternatives should be appealing to adult smokers: they should deliver a taste and sensory experience that leads adult smokers, who would otherwise continue to smoke, to switch.

We can achieve a significant public-health benefit only when a large number of these smokers switch to better products and stop smoking cigarettes altogether.

PMI's vision for a smoke-free future (without cigarettes)


Silhouette of woman in a building overlooking a lake

We’re investing in people, resources, time, and money to develop and assess the risk-reduction potential of these new products. Our innovation pipeline includes four product platforms that can meet the varying preferences of adult smokers and hence help them to switch and stop cigarettes altogether.

In pursuing our vision of reduced-risk products, we are eager to see measures introduced that drive large-scale switching as quickly as possible. We are confident that the right mix of government leadership and commercial initiative will dramatically accelerate efforts to reduce the health burden of smoking.

 1Bilano V, Gilmour S, Moffiet T, d'Espaignet ET, Stevens GA, Commar A, Tuyl F, Hudson I, Shibuya K. (2015) Global trends and projections for tobacco use, 1990–2025: an analysis of smoking indicators from the WHO Comprehensive Information Systems for Tobacco Control. Lancet 385:966-76.

Share this article